In the latest trading session, Marvell Technology (MRVL) closed at $43.78, marking a +0.44% move from the previous day. This change outpaced the S&P 500's 0.63% loss on the day. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
Merck (MRK) closed the most recent trading day at $80.71, moving +0.44% from the previous trading session. This change outpaced the S&P 500's 0.63% loss on the day. Meanwhile, the Dow lost 0.55%, and the Nasdaq, a tech-heavy index, lost 0.1%.
B&G Foods (BGS) closed at $29.26 in the latest trading session, marking a +0.55% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.63%. Meanwhile, the Dow lost 0.55%, and the Nasdaq, a tech-heavy index, lost 0.1%.
McDonald's (MCD) closed at $227.35 in the latest trading session, marking a +0.55% move from the prior day. This move outpaced the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
ServiceNow (NOW) closed the most recent trading day at $518.30, moving +1.81% from the previous trading session. This change outpaced the S&P 500's 0.63% loss on the day. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
In the latest trading session, Barrick Gold (GOLD) closed at $27.96, marking a -0.29% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.63%. At the same time, the Dow lost 0.55%, and the tech-heavy Nasdaq lost 0.1%.
Dropbox (DBX) closed the most recent trading day at $20.34, moving +1.55% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
Galiano Gold (GAU) closed at $1.35 in the latest trading session, marking a -1.46% move from the prior day. This change lagged the S&P 500's 0.63% loss on the day. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
AbbVie (ABBV) closed at $87.83 in the latest trading session, marking a -0.55% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.55%, while the tech-heavy Nasdaq lost 0.1%.
General Electric (GE) closed the most recent trading day at $6.72, moving -1.61% from the previous trading session. This change lagged the S&P 500's daily loss of 0.63%. Meanwhile, the Dow lost 0.55%, and the Nasdaq, a tech-heavy index, lost 0.1%.
Earnings season gets into full swing this week as the big banks start reporting. And within the next few weeks we’ll have a better idea about the impact of the virus and the economy on companies, and therefore, our investments.
Bausch Health Companies Inc. BHC announced that it has acquired an exclusive license for an ophthalmic solution from clinical-stage ophthalmic biopharmaceutical company, Eyenovia EYEN, which is developing a pipeline of microdose array print (MAP) therapeutics.
Analyzing the third-quarter job market data is undoubtedly the best strategy for investors looking to play the upcoming earnings season. September data by the Department of Labor showed that from mid-March through late August, 59.3 million Americans filed for unemployment insura
ServiceNow, Inc NOW recently received a multiyear workflows solutions deal from National Basketball Association (NBA) and Women’s National Basketball Association (WNBA) to ensure safer return to play.
Gilead Sciences, Inc. GILD and Galapagos NV GLPG announced positive results on pipeline candidate, filgotinib, for the treatment of moderately to severely active ulcerative colitis (UC).
Cigna Corp. CI will expand its Medicare Advantage (MA) health plan offerings to seniors in 67 new counties next year in what is quickly becoming a competitive business proposition for health insurance giants.
UnitedHealth Group Inc. UNH will expand its Medicare Advantage (MA) health plan offerings to seniors in 291 new counties next year, in what is quickly becoming a competitive business proposition for health insurance giants.
Sanofi SNY announced that a pivotal phase III study evaluating its blockbuster inflammatory drug Dupixent (dupilumab) to treat uncontrolled moderate-to-severe asthma in children aged from six to 11 years met its primary and all key secondary endpoints.
Seagen Inc. SGEN along with Japanese partner Astellas Pharma, Inc announced positive top-line data from the second cohort of the pivotal phase II EV-201 study, which is evaluating their antibody-drug conjugate Padcev (enfortumab vedotin-ejfv). The drug is being studied for treat
Avenue Therapeutics, Inc. ATXI announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), through which it is seeking approval for its pipeline candidate intravenous (IV) tramadol. The NDA was filed for the candidate to manage moderate-
Checked
6 minutes 59 seconds ago
This feed is responsible for generating the rss feed related to the topic Stocks